Corbus Pharmaceuticals, Inc. - CRBP Net Assets per Single Share

Public company logo of Corbus Pharmaceuticals Holdings, Inc. (CRBP)

The Corbus Pharmaceuticals (CRBP) price chart demonstrates the dynamics of an asset whose strategy is based on partnerships for antibody creation without company mergers, ensuring organic growth. The current indicator is 5.52. The business relies on alliances with global laboratories to accelerate clinical trials and minimizes risks by developing treatments for rare inflammatory conditions and neoplasms for patients with no other alternatives.

CRBP - Corbus Pharmaceuticals Holdings, Inc. Book Value of One Share over the range 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for corbuspharma.com (CRBP)

- price and consensus price forecast:
Stock Price Corbus Pharma|CRBP - Price Target Chart
- market capitalization data:
Market Value Corbus Pharmaceuticals Holdings|CRBP - Full Business Value
- book capitalization data:
Book Value per Share Corbus Pharmaceuticals|CRBP - Book Value of Business|Market Capitalization to Book Value Ratio corbuspharma.com|CRBP - Company Assets
- debt and liquidity data:
Debt to Equity Corbus Pharmaceuticals|CRBP - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Corbus Pharmaceuticals Holdings|CRBP - Company Cumulative Debt|Debt to Book Capitalization Ratio Corbus Pharmaceuticals Holdings|CRBP - Company Long-Term Loans and Borrowings|Company Short-Term Debts Corbus Pharmaceuticals
Fundamental company valuation:CRBP Corbus Pharma
Manufactured product of corbuspharma.com

Book value per share reflects the issuer's net assets minus all liabilities, allowing an assessment of the company's actual capital through a historical book value per share chart. Growth in this metric for Corbus Pharmaceuticals (CRBP) confirms financial stability, which is supported by the diversification of monoclonal antibody production lines and logistics optimization, minimizing raw material disruption risks while maintaining high profitability.

Competitors of Corbus Pharmaceuticals (CRBP)

INCY - Book Value per Share|HCM: Net Assets per Single Share|Net Assets per Single Share Nuvation Bio Inc. (NUVB)|dayonebio.com (DAWN) - Share Book Value|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRDF: Net Asset Value per Share|Net Assets per Single Share BeyondSpring Pharma BYSI|BioAtla (BCAB) - Accounting Value of a Share|LIXT (Lixte Biotechnology) - Book Value per Share|Book Value per Share CTXR|Net Assets per Single Share Cellectar Biosciences, Inc. (CLRB)|Net Assets per Single Share BioLineRx Ltd BLRX|Accounting Value per Share Can-Fite BioPharma, Ltd.|Aprea Therapeutics Inc. - Accounting Value of a Share|KZIA (Kazia) - Net Assets per Single Share|SLXN: Net Asset Value per Share|Net Assets per Single Share nucana.com|Chimerix Inc. (CMRX) - Equity per Share|Book Value per Share CYCC|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share